109 related articles for article (PubMed ID: 37354638)
1. Connexin43 is associated with the progression of clear cell renal carcinoma and is regulated by tangeretin to sygergize with tyrosine kinase inhibitors.
Lai Y; Wu W; Liang X; Zhong F; An L; Chang Z; Cai C; He Z; Wu W
Transl Oncol; 2023 Sep; 35():101712. PubMed ID: 37354638
[TBL] [Abstract][Full Text] [Related]
2. Activation and function of receptor tyrosine kinases in human clear cell renal cell carcinomas.
Zhang Q; Liu JH; Liu JL; Qi CT; Yan L; Chen Y; Yu Q
BMC Cancer; 2019 Nov; 19(1):1044. PubMed ID: 31690270
[TBL] [Abstract][Full Text] [Related]
3. Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation.
Marona P; Górka J; Kwapisz O; Jura J; Rys J; Hoffman RM; Miekus K
Cell Death Dis; 2022 Sep; 13(9):814. PubMed ID: 36138026
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
5. Dyskerin and telomerase RNA component are sex-differentially associated with outcomes and Sunitinib response in patients with clear cell renal cell carcinoma.
Yuan H; Qin X; Yang Q; Liu L; Fang Z; Fan Y; Xu D
Biol Sex Differ; 2023 Jul; 14(1):46. PubMed ID: 37434223
[TBL] [Abstract][Full Text] [Related]
6. A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.
Liu W; Ren D; Xiong W; Jin X; Zhu L
J Exp Clin Cancer Res; 2022 Jan; 41(1):38. PubMed ID: 35081978
[TBL] [Abstract][Full Text] [Related]
7. Association between copy-number alteration of +20q, -14q and -18p and cross-sensitivity to tyrosine kinase inhibitors in clear-cell renal cell carcinoma.
Wang L; Li Y; Lyu Y; Wen H; Feng C
Cancer Cell Int; 2020; 20():482. PubMed ID: 33041663
[TBL] [Abstract][Full Text] [Related]
8. Key sunitinib-related biomarkers for renal cell carcinoma.
Peng Y; Dong S; Song Y; Hou D; Wang L; Li B; Wang H
Cancer Med; 2021 Oct; 10(19):6917-6930. PubMed ID: 34402193
[TBL] [Abstract][Full Text] [Related]
9. PTPRO predicts patient prognosis and correlates with immune infiltrates in human clear cell renal cell carcinoma.
Gan J; Zhang H
Transl Cancer Res; 2020 Aug; 9(8):4800-4810. PubMed ID: 35117843
[TBL] [Abstract][Full Text] [Related]
10. Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma.
Beuselinck B; Verbiest A; Couchy G; Job S; de Reynies A; Meiller C; Albersen M; Verkarre V; Lerut E; Méjean A; Patard JJ; Laguerre B; Rioux-Leclercq N; Schöffski P; Oudard S; Zucman-Rossi J
Acta Oncol; 2018 Apr; 57(4):498-508. PubMed ID: 29095068
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
[TBL] [Abstract][Full Text] [Related]
12. GLUD1 suppresses renal tumorigenesis and development
Wang L; Fang Z; Gao P; Zheng J
Front Oncol; 2022; 12():975517. PubMed ID: 36203437
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
[TBL] [Abstract][Full Text] [Related]
14. Risk signature identification and NPRL2 affects sunitinib sensitivity in clear cell renal cell carcinoma.
Du X; Zhao Z; Zhao X; Wang H; Jiang L; Tang W
Biochem Biophys Res Commun; 2023 Jun; 663():122-131. PubMed ID: 37121122
[TBL] [Abstract][Full Text] [Related]
15. Effect of enhanced expression of connexin 43 on sunitinib-induced cytotoxicity in mesothelioma cells.
Uzu M; Sato H; Yamada R; Kashiba T; Shibata Y; Yamaura K; Ueno K
J Pharmacol Sci; 2015 May; 128(1):17-26. PubMed ID: 26003083
[TBL] [Abstract][Full Text] [Related]
16. Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
Wei Y; Chen X; Ren X; Wang B; Zhang Q; Bu H; Qian J; Shao P
Front Genet; 2021; 12():680369. PubMed ID: 34306023
[TBL] [Abstract][Full Text] [Related]
17.
Wang B; Liu B; Luo Q; Sun D; Li H; Zhang J; Jin X; Cheng X; Niu J; Yuan Q; Chen Y
Transl Cancer Res; 2022 Jul; 11(7):2321-2337. PubMed ID: 35966310
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.
Wierzbicki PM; Klacz J; Kotulak-Chrzaszcz A; Wronska A; Stanislawowski M; Rybarczyk A; Ludziejewska A; Kmiec Z; Matuszewski M
Int J Oncol; 2019 Aug; 55(2):371-390. PubMed ID: 31268155
[TBL] [Abstract][Full Text] [Related]
19. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of placenta specific 8 is associated with malignant progression and poor prognosis of clear cell renal cell carcinoma.
Shi L; Xiao L; Heng B; Mo S; Chen W; Su Z
Int Urol Nephrol; 2017 Jul; 49(7):1165-1176. PubMed ID: 28349447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
